Cardiovascular Research Advance Access [Accepted Manuscript] published online on September 20, 2007
Cardiovascular Research, doi:10.1093/cvr/cvm024
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long Chain n-3 Polyunsaturated Fatty Acids Reduce Atrial Vulnerability in a Novel Canine Pacing Model
a Keenan Research Center in the Li Ka Shing Knowledge Institute at St. Michael's Hospital, Toronto, ON, Canada
b Division of Cardiology, St. Michael's Hospital, Toronto, ON, Canada
c Department of Medicine, University of Toronto, Toronto, ON, Canada
d Department of Human Biology and Nutritional Sciences, University of Guelph, Guelph, ON, Canada
e Bioimaging, St. Michael's Hospital, Toronto, ON, Canada
f University of Melbourne, Department of Medicine, St. Vincent's Hospital, Victoria, Australia
g Department of Surgery, University of Toronto and Terrence Donnelly Cardiovascular Laboratories, St. Michael's Hospital, Toronto, ON, Canada
h Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Corresponding Author Paul Dorian, MD; St. Michael's Hospital; Division of Cardiology; 30 Bond St., 6-050Q; Toronto, ON M5B 1W8; Canada. Tel/Fax: 416-864-5104email: dorianp{at}smh.toronto.on.ca
Aim: Our objective was to assess the effect of omega-3 polyunsaturated fatty acids (n-3 PUFAs) on atrial fibrillation (AF) vulnerability and atrial structure in a new model of atrial cardiomyopathy.
Methods: Dogs were studied in three groups: 7 control dogs (UNPACED) and 24 dogs undergoing simultaneous atrioventricular pacing (for 2 weeks) assigned to placebo treatment (SAVP-PLACEBO, n = 12 dogs) or oral n-3 PUFAs (1 g/day) treatment (SAVP-PUFA, n = 12 dogs).
Results: SAVP-PUFA dogs had less AF inducibility (% of burst attempts leading to AF episodes: 5.5 ± 7.4 vs. 20.4 ± 14.2, p < 0.001) and maintenance (median AF duration: 601 s [377-1216] vs. 1598 s [1195-2400], p < 0.05), than SAVP-PLACEBO dogs. SAVP-PUFA dogs had significantly less local slowing of conduction and conduction heterogeneity than SAVP-PLACEBO dogs. SAVP-PUFA dogs had a significantly smaller increase in atrial matrix metalloproteinase-9 (MMP-9) activity and in collagen type I and III messenger RNA expression (in arbitrary units) than SAVP-PLACEBO dogs (0.62 ± 0.51 vs. 10.80 ± 5.61, respectively for collagen I, p < 0.05); (1.66 ± 0.48 vs. 5.24 ± 1.16, respectively for collagen III, p < 0.05).
Conclusions: N-3 PUFA supplementation can reduce AF vulnerability in a new canine pacing model of atrial cardiomyopathy. The mechanism may be related to attenuation of collagen turnover.
Time for primary review: 33 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Nishida, G. Michael, D. Dobrev, and S. Nattel Animal models for atrial fibrillation: clinical insights and scientific opportunities Europace, October 29, 2009; (2009) eup328v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Laurent, H. Leong-Poi, I. Mangat, G. W. Moe, X. Hu, P. P.-S. So, E. Tarulli, A. Ramadeen, E. I. Rossman, J. K. Hennan, et al. Effects of Chronic Gap Junction Conduction-Enhancing Antiarrhythmic Peptide GAP-134 Administration on Experimental Atrial Fibrillation in Dogs Circ Arrhythm Electrophysiol, April 1, 2009; 2(2): 171 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dorian and B. N. Singh Upstream therapies to prevent atrial fibrillation Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H11 - H31. [Abstract] [Full Text] [PDF]
|
|